These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 16724525

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.
    Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silva P.
    CNS Drug Rev; 2007; 13(3):352-79. PubMed ID: 17894650
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A, Miyachi T, Nakamura T, Ohtsuki T, Kimura Y, Kihira K, Yamawaki T, Matsumoto M.
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [Abstract] [Full Text] [Related]

  • 25. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Off spells and dyskinesias: pharmacologic management of motor complications.
    Khan TS.
    Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
    [Abstract] [Full Text] [Related]

  • 28. [COMT inhibition with tolcapone].
    Nervenarzt; 1996 Jul; 67(7 Suppl Comt-hemmu):1-8. PubMed ID: 9404535
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M, Bosch A, Pedrós C, Figueras A.
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease.
    Nutt JG.
    Adv Pharmacol; 1998 Nov; 42():331-4. PubMed ID: 9327908
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era.
    Ogawa N.
    Eur Neurol; 1997 Nov; 38 Suppl 1():2-5. PubMed ID: 9276193
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.